Acucela secures option to buy retinal technology

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
In PersonPolitics & Policy: Market Impacts and Mid-Year Outlooks
- 06/24/2022
- Sofitel Washington DC Lafayette Square
- 8:30 AM – 12:00 PM ET
Webinar ReplaysExpand Your Perspective: Analyzing Deal Activity & Drivers Across the Capital Markets
- 06/08/2022
- On-Demand
- 1 Hour
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
- ARIA Resort and Casino
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

In This List

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

15 Dec, 2016 | 06:58

Author Ephraim Bie
Theme Healthcare & Pharmaceuticals

Acucela Inc. secured an exclusive option to acquire EyeMedics LLC's proprietary retinal technology for the treatment of certain eye diseases.

While terms of the agreement were not disclosed, Acucela, a Kubota Pharmaceutical Holdings Co. Ltd. subsidiary, noted that the option was acquired under a research and development agreement with the company.